Details for Patent: 7,146,978

Summary for Patent: 7,146,978

Title:	Inhalation device and method
Abstract:	Inhalation device and associated method for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device has a chamber for receiving the receptacle. A ring is circumferentially coupled to an inner surface of the chamber to achieve a higher reproducible emitted dose of medicament from the receptacle. The inhalation device also includes an improved implement for puncturing the receptacle, requiring less force and experiencing fewer failures.
Inventor(s):	David Edwards, Mark DeLong, Craig Dunbar, Ernest E. Penachio, Kevin Stapleton, Mark Wolff
Assignee:	Civitas Therapeutics Inc
Application Number:	US10/771,447
Patent Claim Types: see list of patent claims	Use; Device;

US Patent 7,146,978 Landscape: Scope and Claim-Building Analysis for Powder Inhalation Devices with Ringed Cylindrical Chambers and U-Shaped Staples

US 7,146,978 protects a narrow but mechanically specific method-of-use and device-structure package for dispensing inhalable powder using a particular inhalation flow path architecture: a cylindrical chamber with an internal circumferential ring sized to tighten the inner diameter at the ring, and a substantially U-shaped staple with non-planar edges and angled diamond end faces that punctures a powder receptacle to disperse powder into the chamber for inhalation. The claim set is built to capture both (i) ring geometry tied to performance (“improved” emitted dose) and (ii) receptacle puncture mechanisms including multiple ways of driving the staple, plus (iii) staple geometry details, plus (iv) inhalation dosing parameters (notably a flow-rate limit in the dependent apparatus-style method claim).

---

What is US Patent 7,146,978, and what invention does it claim?

US 7,146,978 claims methods for dispensing inhalable powder using a powder inhalation device. The core claim theme combines three constrained elements:

1. Dispensing flow path geometry
   A cylindrical chamber defined by a straight wall of circular cross-section, with an internal circumferential ring whose inner diameter is smaller than the chamber’s inner diameter, positioned at specific locations (proximal end or midpoint).

2. Receptacle puncturing mechanism
   A substantially U-shaped staple with rounded portion, two prongs, and non-planar inner and outer edges, where the staple is manufactured from a rectangular length with angled diamond-shaped end surfaces. The staple punctures a receptacle (typically a blister/pack or rupturable reservoir insert) to disperse powder into the chamber.

3. Inhalation through a hemispheric aperture region
   The inhalation portion has a hemispheric region with plurality of apertures positioned at the proximal end when coupled first and second casing portions. A dependent claim ties inhalation to the mouth or nose.

The independent claim (Claim 1) reads like a method claim that is drafted around a specific device configuration: it recites the device structure as steps antecedent to the method. Dependent claims narrow puncture mechanics and staple/ring dimensional features.

---

What are the key independent claim elements in Claim 1, and how tightly are they constrained?

Claim 1: “method for dispensing powder by inhalation”

Claim 1 includes the following required limitations (in practical infringement analysis, every element matters):

• Providing a powder inhalation device with:

  • A first casing portion
  • A cylindrical chamber with:
    • a straight wall of circular cross-section
    • proximal end and distal end
    • configured to receive a receptacle
    • an internal circumferential ring coupled to the inner surface
      • and an inner diameter of the ring less than the inner diameter of the chamber
  • A second casing portion removably coupled
    • including an inhalation portion disposed at the proximal end of the chamber when coupled
    • the inhalation portion has a hemispheric region defining plurality of apertures to emit powder

• Puncturing step

  • puncturing the receptacle to disperse powder in the chamber

• Inhaling step

  • inhaling the powder through the inhalation portion

Infringement-relevant constraints

• The “ring smaller than chamber” requirement is broad in concept but still structural and measurable (inner diameter at the ring vs. chamber).
• The hemispheric region with plurality of apertures ties the device interface to a specific geometry. Designs with different aperture shapes or non-hemispheric regions can fall outside.
• The claim is a method claim but is drafted to require a particular device construction “provided” and used in the method.

---

What do the dependent claims add to narrow scope (puncture mechanics, mouth/nose, ring ratio, and ring location)?

Mouth vs nose

• Claim 2: inhaling through a mouthpiece into the user’s mouth
• Claim 3: inhaling through a nose piece into the user’s nose

These create two alternate design capture points. A device that only supports one route may still implicate only one.

How the puncture is actuated (three alternate embodiments)

Claim 4–6 provide multiple ways to drive puncturing, each still tied to a staple puncturing at least two holes:

• Claim 4: move first and second casing portions toward each other; a staple punctures at least two holes
• Claim 5: compress a spring so a staple punctures at least two holes
• Claim 6: move the staple directly so it punctures at least two holes

This structure makes it harder to design around by changing only actuation approach, since the claim family explicitly covers multiple actuation modalities.

Ring-to-chamber inner diameter ratio

• Claim 8: ring inner diameter / chamber inner diameter is about 0.9 or less
• Claim 9: ratio is about 0.8

These are numerical constraints that narrow the set of devices captured by those dependent claims, while Claim 1 only requires “less than.”

Ring axial position

• Claim 12: ring at approximately the midpoint of the chamber
• Claim 13: ring adjacent the proximal end of the chamber

Designs that place the ring elsewhere may avoid these dependent claim positions, but still could implicate Claim 1 if they satisfy “ring smaller than chamber” with any location.

---

What is the staple geometry protected, and how specific are the “non-planar edges” and “angled diamond end surfaces”?

Claim 10–11: the staple defines a protected mechanical profile

Claim 10 introduces a detailed staple definition:

• Substantially U-shaped staple with:
  • rounded portion
  • two prongs
  • prongs define non-planar inner edge and non-planar outer edge
• Manufacturing geometry:
  • staple formed from a rectangular length
  • has two end surfaces and four planar side surfaces
  • intersect to form four non-planar edges
  • defines inner edge as one non-planar edge and outer edge as the opposite non-planar edge
• End surfaces:
  • each end surface is an angled diamond-shaped surface

Claim 11 adds the cutting-point structure:

• each end surface has:
  • top point at apex of the inner edge
  • bottom point at apex of the outer edge
• the top point forms a cutting point for one prong

Design-around implications

Because Claims 10–11 lock in the staple’s edge planarity characteristics and end-surface shape, the strongest avoidance path is to use:

• a different puncturing element (knife edge, wheel, piercer pin, blister blade) with planar edges only, or
• a different end-surface profile (non-diamond end faces), or
• a staple that is not “substantially U-shaped” with the rounded portion and two prongs as defined.

If the staple used is a generic two-prong fork or a planar-edged staple, it may still puncture but may miss these geometry limitations.

---

What is Claim 14, and how does it expand beyond Claim 1?

Claim 14: second “method for dispensing powder” with explicit flow-rate and integrated staple/aperture limitations

Claim 14 is an additional method claim that is closer to an apparatus-structured method. It recites:

• providing a powder inhalation device comprising:
  • a casing with at least one aperture to emit emitted dose
  • a cylindrical chamber with:
    • internal ring (circumferentially coupled to inner surface)
    • a substantially U-shaped staple as defined in Claim 10
  • puncturing a receptacle with the substantially U-shaped staple to disperse powder in the chamber
  • inhaling the emitted dose through the at least one aperture at a flow rate less than about 15 L/min

Dependent narrowers on Claim 14

• Claim 15: same staple end top/bottom point cutting-point structure as Claim 11
• Claim 16: ring at approximately midpoint
• Claim 17: ring adjacent proximal end

Why Claim 14 matters commercially

The flow-rate limitation can be decisive in product positioning and testing. Many DPIs operate over a range of inhalation flows; Claim 14 targets systems that deliver the emitted dose through the aperture at <15 L/min. If a competitor’s intended use requires higher flow for dispersion, it may avoid Claim 14 while still risking Claim 1 depending on structural overlap.

---

How strong is the “ring improves emitted dose” performance linkage in Claim 1?

Claim 1 includes “whereby emitted dose from said powder inhalation device is improved compared to a device with no ring.” In practice, this is both:

• helpful for claim construction (it indicates the ring is not incidental), and
• potentially vulnerable if interpreted as a result-dominated clause tied to subjective performance.

However, the performance language is supported by concrete structural limitations that must be present anyway:

• ring circumferentially coupled to inner surface
• ring inner diameter less than chamber inner diameter

That means infringement arguments can still anchor on structure and geometry even if the “improved emitted dose” comparison becomes litigated.

---

Patent landscape framing: what competitive designs are most at risk under this claim set?

Because the claims are drafted as method claims tethered to device structure, the risk profile tracks design overlap in:

High-risk design overlap

• Cylindrical DPI chamber with a circumferential internal ring narrowing the inner diameter
• Aperture emission interface includes a hemispheric region with plurality of apertures
• Puncturing mechanism uses a substantially U-shaped staple with:
  • non-planar inner and outer edges
  • rectangular-length-derived non-planar edge formation
  • angled diamond end surfaces
  • at least two holes punctured in the receptacle

Medium-risk overlap

• Ring present but placed in a different axial location than midpoint/proximal end
• Actuation method differs from casing-move/spring/direct move (though Claim 4–6 cover multiple actuation modes)
• Device uses U-shaped puncture but staple edge/end geometry differs slightly from “diamond-shaped” or “non-planar edges”

Lower-risk design overlap

• No internal ring or ring not sized to produce the “inner diameter less than chamber” relationship
• Puncturing performed by a different element type (pin arrays, rotating blades, frangible seals) that is not a U-shaped staple with the specified end-face and edge constraints
• Inhalation aperture region not a hemispheric region, or emission through a different internal architecture

---

What claim-to-design mapping would a litigation team focus on?

Even without the full prosecution history, the claim language dictates an evidence plan:

For ring limitations

• Measure ring inner diameter and chamber inner diameter at the defined locations
• Confirm ring circumferential coupling to inner surface and “ring disposed at midpoint/proximal” if chasing dependent claims

For inhalation interface

• Confirm presence and geometry of “hemispheric region” and “plurality of apertures”
• Map mouthpiece/nosepiece configurations to Claims 2–3

For puncture mechanics

• Demonstrate that puncturing produces at least two recepture holes (for Claims 4–6)
• Identify actuation path: casing move vs spring compression vs staple movement

For staple geometry

• Create drawings or metrology records showing non-planar inner and outer edges
• Validate end surfaces: “angled diamond-shaped surfaces”
• Validate cutting-point top/bottom apex features (Claims 10–11, 15)

For flow rate

• Testing or label claims documenting inhalation flow rates enabling emitted dose through apertures
• Compare to “less than about 15 L/min” for Claim 14

---

What is known from the claim set alone about expiration and regulatory posture?

The prompt provides only claim text. It does not provide:

• filing date and jurisdictional priority specifics,
• patent issuance date confirmation,
• whether this is a DPI drug product patent tied to a particular NDA/ANDA/BLA,
• Orange Book listing, exclusivity, or Hatch-Waxman procedural history.

Given these constraints, this analysis does not include a timeline of exclusivity, expiration dates, or Paragraph IV risks, because those depend on bibliographic and FDA listing data not included in the prompt.

---

Key Takeaways

• US 7,146,978 is anchored to a DPI dispensing architecture combining a ringed cylindrical chamber and a highly specific substantially U-shaped staple puncture mechanism.
• Claim scope is split between:
  • structural/dimensional ring features (ring inner diameter smaller than chamber; dependent ratio limits; axial location),
  • inhalation interface geometry (hemispheric aperture region; mouthpiece/nosepiece dependent routes),
  • puncture actuation modes (casing movement, spring compression, staple movement),
  • and staple geometry (non-planar edges and angled diamond end faces) plus a flow-rate limitation in Claim 14 (<15 L/min).
• The most effective design-around routes are removing the internal ring feature, changing puncture element geometry away from the defined staple profile, or changing inhalation aperture architecture away from a hemispheric region and/or flow-rate regime.

---

FAQs

1. Do Claims 1 and 14 require exactly the same ring position (midpoint vs proximal)?
   Claim 1 requires a ring with smaller inner diameter but does not require midpoint/proximal positioning; Claims 16–17 add those positions only as dependent limitations.

2. If a competitor uses a U-shaped staple but with planar edges, is it outside Claims 10–11?
   Likely, because Claims 10–11 define “non-planar inner edge” and “non-planar outer edge” plus specific non-planar edge formation and angled diamond end surfaces.

3. Can a design avoid Claim 14 by targeting inhalation flows above 15 L/min?
   The flow-rate limit is a specific element of Claim 14 (“less than about 15 L/min”), so a device used only at higher flow conditions may avoid that dependent claim’s scope, while still risking Claim 1.

4. What puncture actuation differences are explicitly covered?
   Claims 4–6 cover puncturing by moving casing portions, compressing a spring, or directly moving the staple, as long as the staple punctures at least two holes.

5. Does the inhalation interface need to be a mouthpiece for all claims?
   No. Claims 2 and 3 add mouthpiece or nose piece alternatives as dependent claim options; Claim 1 requires inhaling through the defined inhalation portion but does not restrict route in the independent claim text provided.

---

References

1. US Patent 7,146,978 (claim text provided in prompt).

Drugs Protected by US Patent 7,146,978

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,146,978

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	316397
Austria	394136
Australia	2002255808
Australia	2002334929
Canada	2444129
Canada	2477653
Cyprus	1108214